-
Lupin's Pithampur Unit Gets Health Canada Clearance
Lupin has said that its Pithampur unit 2 manufacturing facility located in Indore has been cleared by Health Canada after a review. “Following the re...
2018-04-12 14:01 -
Indian Pharma and Medical Devices Firms Likely to Benefit from New Chinese Norms
Indian pharmaceutical and medical equipment manufacturers are set to gain in the China market, thanks to new regulatory norms notified by the Chinese ...
2018-04-12 13:56 -
FDA Approves Novartis’ Afinitor
The FDA has approved Novartis’ Afinitor DISPERZ® (everolimus tablets for oral suspension), for the adjunctive treatment of adult and pediatric patie...
2018-04-12 13:50 -
M&A In the Indian Pharmaceuticals Industry Slows in 2017 - Ravi Raghavan
The mergers and acquisitions (M&A) scene in the Indian pharmaceutical industry has been quite vibrant for the last several years, but there are signs ...
2018-04-12 10:34 -
AZ Buys Ionis’ NASH Candidate
AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million.
2018-04-11 11:27 -
vTv’s Azeliragon is Latest Alzheimer’s Drug Failure
The North Carolina-based firm had been trying a different approach than the big pharma companies and had attempted to inhibit a protein called Recepto...
2018-04-11 11:27 -
Does Novartis’s Acquisition of AveXis Spell Trouble for Biogen?
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-ba...
2018-04-11 11:27 -
Epigenetics-Focused Biotech Constellation Raises $100M
Constellation Pharmaceuticals, a company focused on developing small molecule therapies for difficult-to-treat cancers has raised $100 million from a ...
2018-04-11 11:27 -
GW Pharma and Orchard Biggest UK Biotech Fundraisers In Q1
A new BIA/Informa Biotech Financing Update covering the December 2017 to February 2018 period looks at all the funding routes for the sector, and the ...
2018-04-11 11:27 -
Novartis Inks $8.7B Deal to Acquire AveXis
Novartis has entered an agreement to buy AveXis Inc., a gene therapy company, for $8.7 billion dollars as part of its neuroscience strategy.
2018-04-11 11:10
Hot News
- BASF’s Big Restructuring: Cut... Sep 01, 2025
- German Chemical Industry Outpu... Sep 15, 2025
- DuPont Bids Farewell to Its Ar... Sep 02, 2025
- ExxonMobil Eyes $1 Billion Pet... Sep 16, 2025
- FDA Clears Sanofi’s Wayrilz (... Aug 31, 2025
Related Products
Related Producers
